Contrave News
Most Popular Contrave Story
Orexigen surges on FDA trial pact for troubled weight loss drug
Shares of Orexigen Therapeutics ($OREX) shot up 18% yesterday after the biotech laid out a special protocol assessment pact with the FDA, detailing the design of a big new safety study of its weight Read more...
Latest Headlines
- February 7, 2012
- September 21, 2011
- February 10, 2011
- February 2, 2011
- February 1, 2011
- January 28, 2011
- December 13, 2010
- December 7, 2010
- December 6, 2010
- December 3, 2010
- November 30, 2010
- October 25, 2010
- October 11, 2010
- September 2, 2010
- June 29, 2010
- April 13, 2010
Paid Research Reports
- Trends in mHealth and Telemedicine
- The Global Aesthetic Dermatology Market Outlook
- Future Directions in Regenerative Medicine
- Pipeline Insight: Insulin Antidiabetics – Novel analogs show promise as alternative delivery methods prove less attractive
- Pipeline Insight: Non-insulin Antidiabetics - Rise of the weight-reducers: Once-weekly GLP-1 agonists and novel SGLT-2 inhibitor
- Forecast Insight: Antidiabetics - Diabetes market growth driven by epidemiological trends and rich pipeline
